EUCTR2019-001682-33-CZ进行中（未招募）1 期
A Phase 2a, randomized, double-blind, placebo-controlled, multi-center study to evaluate the effect of GB001 in patients with chronic rhinosinusitis with or without nasal polyps
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- GB001, Inc.
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Informed Consent: Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.
- •2. Age: = 18 to 75 years of age at the time of Screening visit.
- •3. Sex: Males or females:
- •a. Women of childbearing potential (WOCBP) must use an acceptable method of contraception at least 1 month prior to screening through 28 days after the last dose of IP.
- •4. Diagnosis: Diagnosis of chronic rhinosinusitis with or without bilateral nasal polyps for at least 12 weeks prior to Visit 1.
- •5. Nasal symptoms: Presence of at least two of the following symptoms prior to Visit 1:
- •nasal blockade/obstruction/congestion
- •nasal discharge (anterior/posterior nasal drip)
- •facial pain/pressure
- •preduction or loss of smell
- •6. INCS: Subjects must be on a stable administration of intranasal corticosteroids (INCS) for = 2 months prior to Visit 1. For subjects using a specialized delivery device (eg, XHANCE™) or corticosteroids administered via irrigation (eg, budesonide + sterile saline), they must be on MFNS for = 2 weeks prior to screening.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 90
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 10
排除标准
- •1.Nasal symptoms: SNOT-22 score <20 as assessed at screening. 2.Prior polyp surgery: Subjects who have undergone any nasal surgery (excluding polypectomy performed as an outpatient procedure) within 4 months before screening or have had =4 sinonasal surgeries in the past. 3.Comorbidities: Presence of a known pre-existing clinically important condition including: active tuberculosis, pulmonary fibrosis, bronchopulmonary aspergillosis, eosinophilic granulomatous polyangiitis (Churg-Strauss syndrome), Young's syndrome, Kartagener's syndrome or dyskinetic ciliary syndromes, and cystic fibrosis.Clinically significant endocrine, autoimmune, metabolic, neurological, renal (calculated creatinine clearance <60 mL/min), gastrointestinal, hepatic, cardiovascular, hematological, or any other system abnormalities that are uncontrolled with standard treatment. 4.Malignancy: A current malignancy or previous history of cancer in remission for less than 5 years prior to screening (subjects will not be excluded if they had localized carcinoma of the skin that was resected for cure). 5.Liver Disease: Known pre-existing liver disorders (ie, non-alcoholic fatty liver disease (NALFD) or Gilbert's syndrome),or unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices or persistent jaundice), cirrhosis, or known biliary abnormalities. 6.Prior anti-inflammatory treatment: Subjects who have required a burst of systemic corticosteroids (eg, oral, intravenous, intramuscular corticosteroids) within the 1 month before screening or are scheduled to receive systemic corticosteroids during the study period for another condition, or who have required intranasal corticosteroid drops within 1 month prior to screening.
- •7.Intolerant to mometasone furoate nasal spray. 8.Specific conditions/concomitant diseases: Subjects with conditions such as: antrochoanal polyps, nasal septal deviation that would occlude at least one nostril; acute sinusitis, invasive fungal rhinosinusitis, neutrophilic polyposis, nasal infection or upper respiratory infection at screening or in the 2 weeks before screening. Subjects requiring chronic systemic antibiotic treatment for rhinosinusitis. 9.Ongoing rhinitis medicamentosa. 10.ECG Assessment: Subjects with QTcF =450 msec for males or QTcF =470 msec for females on the Screening visit ECG. However, if QTcF is above this prespecified limit and there are no other clinically significant ECG abnormalities in the opinion of the Investigator, the assessment can be repeated in triplicate. The triplicate QTcF values should be averaged by the Investigator to determine eligibility of the subject to enter the Run-in period. However, if any of the triplicate ECGs show a clinically significant abnormality in the opinion of the Investigator, the subject should be excluded, regardless of the average QTcF of the triplicates. 11.Alcohol/Marijuana/Illicit Drugs/Substance Abuse: A known or suspected history of alcohol misuse, marijuana, illicit drugs, or substance abuse within 12 months prior to Screening visit. 12.Smoking history: Asthma or COPD patients that are current smokers (any substance), or former smokers with a smoking history of =10 pack-years [(number of cigarettes per day/20) × number of years smoked]. A former smoker is defined as a subject who quit smoking at least 6 months prior to Screening visit. This includes electronic cigarettes and vaping. 13.Immunodeficiency: A
研究者
相似试验
进行中（未招募）
1 期
A randomized double-blind placebo controlled study combining EYP001a with polymerase inhibitors to improve hepatitis B cure ratesChronic Hepatitis BMedDRA version: 20.1 Level: PT Classification code 10008910 Term: Chronic hepatitis B System Organ Class: 10021881 - Infections and infestationsEUCTR2019-001629-28-PLENYO Pharma SA49
尚未招募
2 期
A Phase 2a, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy, safety, and tolerability of BG00012 when given with methotrexate to subjects with active rheumatoid arthritis who have had an inadequate response to conventional disease-modifying anti-rheumatic drug therapy.Inflammatory and Immune System - Rheumatoid arthritisRheumatoid arthritisACTRN12608000644369Biogen Idec, Inc150
尚未招募
2 期
A Phase 2a study to assess efficacy and safety of VIT-2763 in subjects with sickle cell diseasesickle cell diseasesickle cell disease (SCD) (sickle haemoglobin (HbS)/S or HbS/ßT0genotype)LBCTR2021064783Vifor (International) Inc.25
已完成
2 期
A Phase II, randomized, double-blind, placebo-controlled clinical study to evaluate the efficacy and safety of topical lidocaine spray in patients with Postherpetic NeuralgiaNeurological - Other neurological disordersPostherpetic NeuralgiaACTRN12618000852257Andros Pharmaceuticals Pty Ltd30
进行中（未招募）
1 期
A Study Evaluating the Effects of Lebrikizumab on Airway Eosinophilic Inflammation in Patients with Uncontrolled Asthma.AsthmaMedDRA version: 18.1Level: PTClassification code 10003553Term: AsthmaSystem Organ Class: 10038738 - Respiratory, thoracic and mediastinal disordersEUCTR2014-000275-14-GBF. Hoffmann-La Roche Ltd80